AMINOHIPPURIC ACID

DRUG4 trials

Sponsors

Universitaetsklinikum Erlangen AöR, Universitair Medisch Centrum Groningen, Istituto Di Ricerche Farmacologiche Mario Negri

Conditions

Chronic Kidney Disease Kidney FailureHeart failureMembranous nephropathycardiovascular diseasechronic kidney diseasetype 2 diabetes mellitus

Phase 2

Rescue Therapy with the Human Anti-CD38 Antibody MOR202 (felzartamab) in Patients with Membranous Nephropathy who Failed Anti-CD20 Target Therapy (MONET study)

CompletedCTIS2024-513744-28-00

Istituto Di Ricerche Farmacologiche Mario NegriMembranous nephropathy

Start: 2021-10-22End: 2025-02-21Target: 10Updated: 2024-09-25

Comparative Study on the Mode of Action of Vicadrostat and Spironolactone on Protein Profiles and Renal Hemodynamic Effects in Patients with Heart Failure or Cardiovascular Disease and Chronic Kidney Disease (COMPARE-VS)

Not yet recruitingCTIS2025-523743-35-00

Universitair Medisch Centrum Groningencardiovascular disease, chronic kidney disease, Heart failure

Target: 100Updated: 2026-03-23

Phase 3

Effects of Finerenone on Renal Hemodynamics and Oxidative Stress

CompletedCTIS2023-508266-15-00

Universitaetsklinikum Erlangen AöRtype 2 diabetes mellitus

Start: 2024-01-18End: 2025-11-25Target: 75Updated: 2024-08-16

Phase 4

VALIDGFR; method VALIDation and evaluation of non-radioactive methods to measure Glomerular Filtration Rate

RecruitingCTIS2023-509156-34-02

Universitair Medisch Centrum GroningenChronic Kidney Disease Kidney Failure

Start: 2025-02-24Target: 200Updated: 2025-12-31